Cytodyn Inc (CYDY)

$0.30 +0.00 (1.36%)
Market Cap 384.14M
Revenue (ttm) 0.00
Net Income (ttm) 3.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,545,000
Avg Vol 1,942,708
Day's Range N/A - N/A
Shares Out 1.28B
Stochastic %K 7%
Beta 1.17
Analysts Strong Buy
Price Target $4.00

Company Profile

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has...

Industry: Biotechnology
Sector: Healthcare
Phone: 360 980 8524
Fax: 360 799 5954
Address:
1111 Main Street, Suite 660, Vancouver, United States
SzewczRock_79
SzewczRock_79 Apr. 26 at 1:27 AM
$CYDY 🍀 Six years. Here’s where we stand after AACR 2026. THE EVIDENCE ✅ HIV Phase 3 RCT — 64% vs 23.1%. Published. ✅ mTNBC — HR 4.14 (p=0.0041). 5/5 alive at 60.9 months. ✅ CLOVER CRC — 100% ctDNA response by week 2. 60+ patients enrolled. ✅ GBM — Bliss synergy >11 with standard of care. ✅ MASH — Phase 2a hit primary AND secondary endpoints. THE PATIENTS One mTNBC patient alive at 5 years. One mCRC patient NED at 5 years. One CLOVER patient — KRAS-G12V/MSS, exhausted everything — still on Cycle 7. One mechanism. Six diseases. Nine conferences in 12 months. BP was in that building in San Diego. Current price: $0.2990 Partnership: $3–$8 Acquisition: $10–$20 ASCO in 5 weeks. 🍀🟢🚀 $CYDY
1 · Reply
my69z
my69z Apr. 26 at 12:58 AM
$CYDY A napkin not kicked around: A pharma offer to Cytodyn: Buying 10% of Cytodn. Includes "Plug-n-Play" LL: Manufacturing. Distribution. Marketing. Cytodyn agrees to: *1 Advisory member. *Hire 3 MM's to initiate NASDAQ process 10% / 200m shares. @ $10 share price. $2B cash to Cytodyn. Cytodyn retains full control of it's own destiny: Leronlimab. ...
1 · Reply
my69z
my69z Apr. 26 at 12:16 AM
$CYDY Another 1st LL brings the pharma world: An affective anti-cancer drug, with an unmatched Label for Contract sales & marketing firms. 3rd-parties offer up such phenomenal packages, Cytodyn decides to push frwd? You better believe @ this point, top firms have too been in contact with Cytodyn & Syneos. "...a patient with mTNBC whose cancer had spread to both brain and lungs, but who is alive today without evidence of disease, almost 5 years..." ....
1 · Reply
Bio4
Bio4 Apr. 26 at 12:15 AM
$CYDY a GREAT reminder of the power of Leronlimab in CRC (from 2022) https://www.reddit.com/r/Livimmune/s/sfExYoCJqv
1 · Reply
Twinter11
Twinter11 Apr. 25 at 11:11 PM
$CYDY Little known fact: From the recent filing "Holders The number of record holders of our common stock on April 15, 2026 was approximately 1,000."
1 · Reply
Jesse21SD
Jesse21SD Apr. 25 at 10:22 PM
$CYDY The people heavily manipulating this stock saw the data and aggressively attacked the SP as fast as they could in hopes we would sell as they cover. That says something.
0 · Reply
Betondapill
Betondapill Apr. 25 at 10:17 PM
$CYDY The real indicator to watch will be the topline data from the CLOVER study and whether the FDA grants Breakthrough Therapy Designation based on these AACR posters. If they get BTD, the "likelihood" of approval shifts from a "maybe" to a "probably."
1 · Reply
Djjazzyjeff
Djjazzyjeff Apr. 25 at 10:16 PM
$CYDY the market saw the data and sold as fast as it could. That says something.
1 · Reply
PhyscoChicken
PhyscoChicken Apr. 25 at 10:01 PM
$CYDY Within 2 short weeks we have ctDNA dropping by greater than 50% in 80% of the patients. According to the 2023 poster when ctDNA drops greater than 50% it shows a a correlation to longer overall survival. https://share.google/wh0plOO7juw2kuGQ9 Big pharma gotta be smart enough to see other competitive drugs just overload the system rather than adjust the micro environment then prime and pair. Well thats my take on how the pieces fit, thanks to others research and sharing BioTrends _USA and Cytomight at Reditt https://share.google/dVSUdsbVRNzKJR1ir
1 · Reply
GhostofCytomight
GhostofCytomight Apr. 25 at 9:59 PM
$CYDY I BELIEVE YOU BGT‼️ https://www.reddit.com/r/Livimmune/s/RBUj63rljp
0 · Reply
Latest News on CYDY
No data available.
SzewczRock_79
SzewczRock_79 Apr. 26 at 1:27 AM
$CYDY 🍀 Six years. Here’s where we stand after AACR 2026. THE EVIDENCE ✅ HIV Phase 3 RCT — 64% vs 23.1%. Published. ✅ mTNBC — HR 4.14 (p=0.0041). 5/5 alive at 60.9 months. ✅ CLOVER CRC — 100% ctDNA response by week 2. 60+ patients enrolled. ✅ GBM — Bliss synergy >11 with standard of care. ✅ MASH — Phase 2a hit primary AND secondary endpoints. THE PATIENTS One mTNBC patient alive at 5 years. One mCRC patient NED at 5 years. One CLOVER patient — KRAS-G12V/MSS, exhausted everything — still on Cycle 7. One mechanism. Six diseases. Nine conferences in 12 months. BP was in that building in San Diego. Current price: $0.2990 Partnership: $3–$8 Acquisition: $10–$20 ASCO in 5 weeks. 🍀🟢🚀 $CYDY
1 · Reply
my69z
my69z Apr. 26 at 12:58 AM
$CYDY A napkin not kicked around: A pharma offer to Cytodyn: Buying 10% of Cytodn. Includes "Plug-n-Play" LL: Manufacturing. Distribution. Marketing. Cytodyn agrees to: *1 Advisory member. *Hire 3 MM's to initiate NASDAQ process 10% / 200m shares. @ $10 share price. $2B cash to Cytodyn. Cytodyn retains full control of it's own destiny: Leronlimab. ...
1 · Reply
my69z
my69z Apr. 26 at 12:16 AM
$CYDY Another 1st LL brings the pharma world: An affective anti-cancer drug, with an unmatched Label for Contract sales & marketing firms. 3rd-parties offer up such phenomenal packages, Cytodyn decides to push frwd? You better believe @ this point, top firms have too been in contact with Cytodyn & Syneos. "...a patient with mTNBC whose cancer had spread to both brain and lungs, but who is alive today without evidence of disease, almost 5 years..." ....
1 · Reply
Bio4
Bio4 Apr. 26 at 12:15 AM
$CYDY a GREAT reminder of the power of Leronlimab in CRC (from 2022) https://www.reddit.com/r/Livimmune/s/sfExYoCJqv
1 · Reply
Twinter11
Twinter11 Apr. 25 at 11:11 PM
$CYDY Little known fact: From the recent filing "Holders The number of record holders of our common stock on April 15, 2026 was approximately 1,000."
1 · Reply
Jesse21SD
Jesse21SD Apr. 25 at 10:22 PM
$CYDY The people heavily manipulating this stock saw the data and aggressively attacked the SP as fast as they could in hopes we would sell as they cover. That says something.
0 · Reply
Betondapill
Betondapill Apr. 25 at 10:17 PM
$CYDY The real indicator to watch will be the topline data from the CLOVER study and whether the FDA grants Breakthrough Therapy Designation based on these AACR posters. If they get BTD, the "likelihood" of approval shifts from a "maybe" to a "probably."
1 · Reply
Djjazzyjeff
Djjazzyjeff Apr. 25 at 10:16 PM
$CYDY the market saw the data and sold as fast as it could. That says something.
1 · Reply
PhyscoChicken
PhyscoChicken Apr. 25 at 10:01 PM
$CYDY Within 2 short weeks we have ctDNA dropping by greater than 50% in 80% of the patients. According to the 2023 poster when ctDNA drops greater than 50% it shows a a correlation to longer overall survival. https://share.google/wh0plOO7juw2kuGQ9 Big pharma gotta be smart enough to see other competitive drugs just overload the system rather than adjust the micro environment then prime and pair. Well thats my take on how the pieces fit, thanks to others research and sharing BioTrends _USA and Cytomight at Reditt https://share.google/dVSUdsbVRNzKJR1ir
1 · Reply
GhostofCytomight
GhostofCytomight Apr. 25 at 9:59 PM
$CYDY I BELIEVE YOU BGT‼️ https://www.reddit.com/r/Livimmune/s/RBUj63rljp
0 · Reply
GhostofCytomight
GhostofCytomight Apr. 25 at 9:15 PM
$CYDY CITY OF HOPE #9
0 · Reply
phoenixblaze
phoenixblaze Apr. 25 at 8:54 PM
$CYDY cancer data released. https://x.com/i/status/2048034947416392086
1 · Reply
my69z
my69z Apr. 25 at 7:28 PM
$CYDY Anyone not in-house testing with Leronlimab --- after our very near mCRC 60 data....will risk being left in the medical dust Period !! ...
0 · Reply
my69z
my69z Apr. 25 at 6:50 PM
$CYDY "...a patient with mTNBC whose cancer had spread to both brain and lungs, but who is alive today without evidence of disease, almost 5 years..." No surprise mCRC was later expanded on Inclusions. BOOOM !!! ...
0 · Reply
GhostofCytomight
GhostofCytomight Apr. 25 at 5:27 PM
$CYDY $CYDY Dr.KASI WHEN HE SAW THE ctDNA DROP BY WEEK 2‼️😆
1 · Reply
my69z
my69z Apr. 25 at 4:31 PM
$CYDY Everyone is going to need Leronlimab. Pre-pay for gurantee of supply: R&D. Pre-clinical. Repurpose testing. Post FDA approval. Patent Evergreening. Government stockpiles. D.O.D. priority of supplies. Remaining mCRC comes in-line with expectations or better, even being without mTNBC data yet & Cytodyn is....." in charge of our own destiny " Remember that Dr. J reference ?? BOOOM !!! ... l
1 · Reply
GhostofCytomight
GhostofCytomight Apr. 25 at 3:46 PM
$CYDY “We have a nice poster from ASCO GI 2023 looking at PFS and OS in patients who had a cDNA VS those who didn't. And the findings are striking.” Dr.Kasi
0 · Reply
Djjazzyjeff
Djjazzyjeff Apr. 25 at 3:39 PM
$CYDY as I've stated I will gladly make a forum about me if you want but here we talk about this garbage company and any posts only about me will be reported and blocked. Enjoy the red!
1 · Reply
GhostofCytomight
GhostofCytomight Apr. 25 at 3:24 PM
$CYDY “STRIKING” PINCH ME‼️😆😆😆😆😆😆😆😆😆😆😆😆
3 · Reply
Jiha
Jiha Apr. 25 at 3:15 PM
$CYDY bottom line...when the clinical trials and EAP start showing participants going into remission, that is when we win BIG! feeling
0 · Reply
WagonTrain
WagonTrain Apr. 25 at 3:09 PM
$CYDY Coming to deliver the goods -
1 · Reply
GhostofCytomight
GhostofCytomight Apr. 25 at 2:58 PM
$CYDY OH YES‼️😆 @MGK2
0 · Reply